AstraZeneca Says Tagrisso® (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial
AstraZeneca PLC LSE:AZN
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.